Archive · 25 Jul 2025
Cipla Q1 Profit Rises 10% to ₹1,298 Crore
Cipla, a drug company, made more money in the first three months of 2025 than the same time last year.
Their profits went up by 10%, reaching ₹1,298 crore.
They also earned more overall, with a total income of ₹6,957 crore.
This growth was helped by good sales in India, Europe, and Africa.
Their business in India did well, but sales in North America decreased a little.
The company plans to focus on growing in important markets, developing their main brands, and investing in new products.
Cipla's consolidated profit after tax (PAT) rose 10% to ₹1,298 crore in Q1 2025.
Total income from operations increased to ₹6,957 crore for the June quarter.
One-India business grew 6% year-on-year during the quarter.
Sales in the Indian market rose to ₹3,070 crore, a 6% increase.
North America sales declined 7% year-on-year to ₹1,933 crore.
- Who
- Cipla, a drug major.
- What
- Cipla reported a 10% increase in consolidated profit after tax for Q1 2025.
- When
- For the first quarter ended June 30, 2025.
- Where
- The report covers Cipla's financial performance, including markets in India, North America, Europe, and Africa.
- Why
- The increase was aided by robust sales growth in India, Europe, and Africa.
- PAT (Q1 2025)
- ₹1,298 crore
- PAT (Q1 2024)
- ₹1,178 crore
- Total Income (Q1 2025)
- ₹6,957 crore
- Total Income (Q1 2024)
- ₹6,694 crore
- India Sales Growth
- 6%
- North America Sales Decline
- 7%